BiO2 Medical Inc.
Prophylactic pulmonary embolism protection
This article was originally published in Start Up
Hospitalized patients are at the greatest risk for a fatal pulmonary embolism within the first 10 days after admission, but traditional inferior vena cava filters to prevent PEs if anticoagulant therapy is contraindicated and/or ineffective are not typically placed in a patient until approximately one week into their hospital stay. BiO2 Medical Inc. is looking to address this treatment gap with its Angel Catheter, a device that incorporates the PE protection of a retrievable, self-expanding nitinol IVC filter attached to a triple-lumen, central venous access catheter.
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
A review by a government watchdog found the FDA’s review process for COVID-19 diagnostics was plagued by issues including allowing low-quality tests to slip through, high reviewer workloads, and manufacturer frustration.
New trial data shows Boston Scientific’s Sentinel cerebral embolic protection device may reduce the risk of disabling stroke, but it does not appear to reduce the overall risk of stroke.